Skip to main content
. 2023 Nov 8;9(4):e003426. doi: 10.1136/rmdopen-2023-003426

Table 3.

Definitions of SSc-ILD progression based on the combination of multiple parameters

SSc mixed cohorts SSc-ILD cohorts
Time, months
(n papers)
n patients (n papers) n ILD patients (n papers) n progressors
(n papers)
References Time frame, months
(n papers)
n patients (n papers) n progressors (n papers) References
PFTs
 Decline FVC>10% or DLCO>15% 6 (1)
12 (6)
24 (3)
>36 (5)
>60 (1)
Unk (6)
10 476 (18) 4258 (14) 1144 (14) 8 70 116 117 148 208 213–225 6 (1)
12 (9)
24 (4)
36 (1)
>60 (3)
Unk (8)
1571 (22) 461 (18) 32 38 123 152 153 226–241
 Decline FVC>10% or DLCO>10% 6 (1)
12 (2)
>36 (4)
60 (1)
531 (8) 336 (8) 181 (8) 174 205 242–245 12 (1)
24 (1)
36 (2)
>36 (2)
489 (6) 47 (4) 121 246–250
 Decline FVC>10% and/or decline FVC 5%–9% with decline DLCO>15% 6 (1)
12 (2)
24 (1)
878 (4) 495 (4) 110 (4) 251–254 12 (2)
Unk (1)
772 (3) 96 (1) 154 192 255
PFTs+HRCT
 Decline FVC≥10% or DLCO≥15% or ILD extent increase>20% 12 (1)
21 (1)
24 (1)
462 (3) 204 (3) 55 (3) 113 256 257 12 (1)
56 (1)
72 (2) 15 (2) 258
PFTs or HRCT+clinical signs
 Decline FVC>10% or decline FVC 5%–10% and worsening
 f respiratory symptoms or/and increase ILD extent
24 (1) 36 (1) 22 (1) 9 (1) 259 12 (1)
36 (1)
Unk (1)
109 (3) 48 (1) 260–262

DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; HRCT, high-resolution CT; ILD, interstitial lung disease.